Improved D-Allulose Biosynthesis by Growth-Coupled Evolution of Epimerase Using Biosen

Enzyme performance decides your allulose cost

A granulated sugar replacement only succeeds if the rare sugar behind it is affordable. D-allulose price starts with the epimerase. Researchers have now shown a smarter way to evolve that enzyme. The mutant they isolated is 6.28 times more active than the starting enzyme. Its half-life at 60°C is 2.5 times longer. It converts D-fructose to D-allulose at 32.2% in three hours. That is not a marginal tweak.

Why epimerases matter for allulose production

D-allulose is a rare sugar. It tastes like sucrose but delivers almost no calories. Commercial production usually starts with D-fructose. Ketose 3-epimerases, KEases for short, rearrange the hydroxyl group at C3. The result is D-allulose.

There is a catch. Many epimerases are slow and heat-sensitive. Sugar processing lines run hot. If the enzyme falls apart, conversion drops. A more stable enzyme extends run times and lowers enzyme loading.

Screening many mutants is the real bottleneck. Traditional directed evolution uses microtiter plates and chromatographic or colorimetric assays. Those methods are accurate but slow. They limit how many variants you can test.

How the study worked

The group built a growth-coupled in vivo screening platform using Biosen, a D-allulose-dependent biosensor. Cells that make more D-allulose trigger the sensor and grow faster. Enzyme activity drives survival. That link turns evolution into a growth competition.

The researchers applied the platform to a ketose 3-epimerase. They isolated the ADAE mutant M42. This is not just one lucky mutant. It is a screening system that can be reused for future rounds of evolution.

What the data show

The numbers stand out on their own.

Performance measure	Starting enzyme	M42 mutant
Catalytic activity	1x baseline	6.28x higher
Half-life at 60°C	1x baseline	2.5x longer
D-allulose from D-fructose at 3 h	not reported	32.2%

The conversion number matters. 32.2% in three hours is strong for ketose epimerases, especially when combined with improved thermostability. High activity alone is not enough in a factory. You need an enzyme that survives process conditions. M42 addresses both.

What this means for formulators and buyers

Enzyme suppliers can shorten development cycles. They can screen larger libraries in less time. That means better biocatalysts reach the market faster.

For formulators, a more active enzyme can reduce the amount of enzyme needed per batch. A more stable enzyme can tolerate higher temperatures and more reuse cycles.

For ingredient buyers, the effect is indirect but real. Lower enzyme costs and more efficient conversion reduce the production cost of D-allulose. More efficient production also supports supply security. The paper does not say M42 is commercial now. But the method points toward a more consistent future supply.

Questions formulators often ask

Q: Is a biosensor screen only useful for D-allulose?

The screen is built around D-allulose-dependent gene expression. It works for KEases that make D-allulose. Other enzymes would need their own sensor.

Q: How does growth coupling speed up evolution?

Instead of testing each variant manually, cells self-select. The more D-allulose they make, the faster they grow. The best variants dominate the population quickly.

Q: Can I buy M42 today?

The paper does not state that M42 is commercially available. It is a research-stage enzyme. The reusable screening platform is the bigger story for the industry.

This is the type of work that moves D-allulose from a niche sweetener toward a commodity. Better enzymes mean less waste, less energy, and lower cost. If you buy D-allulose, watch how suppliers evolve their biocatalysts. The one that runs longer and converts faster will likely win the next contract.